AYTU BIOPHARMA CEO Joshua Disbrow Receives 30,000-Share Award

What Happened
Joshua R. Disbrow, CEO of AYTU BIOPHARMA, INC. (AYTU), received a grant/award of 30,000 restricted shares on July 28, 2026. The reported acquisition price is $0.00 (grant), so no cash was paid in the transaction (transaction code A).

Key Details

• Transaction date: July 28, 2026; Form filed July 30, 2026 (timely within the standard two-business-day window).
• Shares granted: 30,000 restricted shares; reported acquisition price: $0.00.
• Shares owned after transaction: not specified in the provided filing summary.
• Footnote (F1): Vesting schedule — 1/3 vests on July 28, 2027; the remaining shares vest in eight equal quarterly installments beginning October 28, 2027.
• Transaction type: Award/Grant (code A). No indication of a 10b5-1 plan, gift, sale, or tax-withholding in the provided details.

Context
This is a compensation-related restricted stock grant that vests over time rather than an open-market purchase or sale. Such grants are common for executive compensation and do not by themselves indicate immediate buying or selling pressure in the market; they align future executive incentives with company performance.